<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497000</url>
  </required_header>
  <id_info>
    <org_study_id>Peking UPH</org_study_id>
    <nct_id>NCT03497000</nct_id>
  </id_info>
  <brief_title>Effects of OCTA-guided PDT in Acute CSC</brief_title>
  <official_title>Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      OCTA-guided PDT is as safe and effective as ICGA-guided PDT in the treatment of acute central
      serous chorioretinopathy. Or OCTA-guided PDT is more effective than ICGA-guided PDT in the
      treatment of acute central serous chorioretinopathy, safe as well.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with subretinal fluid resolution on OCT after PDT of two groups</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with leakage point resolution on FFA after PDT of two groups</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of recurrent CSC after PDT of two groups</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA (best corrected visual acuity) at every follow-up of two groups</measure>
    <time_frame>1 month, 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <condition>Tomography, Optical Coherence</condition>
  <arm_group>
    <arm_group_label>OCTA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group underwent OCTA-guided half-dose photodynamic therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICGA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>OCTA-guided Photodynamic therapy</intervention_name>
    <description>Half-dose photodynamic therapy using verteporfin under the guidance of OCTA</description>
    <arm_group_label>OCTA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ICGA-guided Photodynamic therapy</intervention_name>
    <description>Half-dose photodynamic therapy using verteporfin under the guidance of ICGA</description>
    <arm_group_label>ICGA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic detachment of the neurosensory retina with a focal leak at the level of the
             RPE with FA

          -  Presence of SRF and/or serous pigment epithelial detachment on OCT

          -  Presence of abnormal dilated choroidal vasculature in ICGA

        Exclusion Criteria:

          -  Patients with other ocular conditions commonly associated with SRF, such as choroidal
             neovascularization, polypoidal choroidal vasculopathy (PCV), diabetic retinopathy,
             retinal vascular occlusion, Coat's disease

          -  Any disease that may affect the quality of imaging (quality of OCTA images &lt; 6), such
             as cataract, high myopia or nystagmus

          -  History of ocular surgeries including retinal laser

          -  Pregnancy

          -  Any uncontrolled systemic disease

          -  Any condition rendering patients intolerable to image acquisition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingwei Zhao, M.D</last_name>
    <role>Study Director</role>
    <affiliation>People's Hospital of Peking University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>People's Hospital of Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 14, 2018</last_update_submitted>
  <last_update_submitted_qc>April 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Mingwei Zhao</investigator_full_name>
    <investigator_title>Head of Ophthalmology, Professor</investigator_title>
  </responsible_party>
  <keyword>optical coherence tomography angiography</keyword>
  <keyword>central serous chorioretinopathy</keyword>
  <keyword>photodynamic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

